cell therapy
Canada Backs Aspect Biosystems With $280M to Scale Bioprinted Tissue Therapies
The Government of Canada is supporting bioprinting company Aspect Biosystems with a new $280 million project to help develop and manufacture its bioengineered cellular medicines. The project will run over…
Aspect Biosystems Expands Novo Nordisk Partnership, Signaling Broader Pharma Interest
Aspect Biosystems and Novo Nordisk are expanding their partnership. The duo had previously made a deal worth up to $2.6 billion in 2023. Then the deal centered on drug discovery…
BiologIC Technologies Promises the Dawn of Biocomputing
Biotech firm BiologIC Technologies is pioneering a new era in the field of biotechnology with the creation of the world’s first biocomputer. The biocomputer, a novel machine built from highly integrated…
Aspect Biosystems Strikes $2.6B Bioprinted Tissue Deal with Novo Nordisk
Bioprinting collaborations are heating up in 2023. In one of the biggest moves of the bioprinting industry, Canadian startup Aspect Biosystems and Danish pharma giant Novo Nordisk (CPH: NOVO-B) struck…
Cell Culture Startup to Tackle Heart Disease with Mitsubishi, Sumitomo and Toppan
Kyoto University spinout Myoridge was founded in 2016 as a bioventure, piggybacking on patented technology developed at the university’s Institute for Integrated Cell-Material Sciences (iCeMS). Since then, the company cultivates…
